Dehaier Medical Announces Improved Sleep Diagnostics Device

        Print
| Source: Dehaier Medical Systems Limited

BEIJING, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Dehaier Medical Systems Ltd. (Nasdaq:DHRM) ("Dehaier" or the "Company"), an emerging leader in development, assembly, marketing and sales of medical devices and homecare medical products, announced today that it has completed research and development for its new DHR-998 sleep diagnostics device. The new device is a technological upgrade based on the original high efficiency sleep diagnostic and monitoring product. The device, which features an enhanced and more user-friendly operating system, analyzes user respiratory quality more accurately across five testing variables, PPG (plethysmograph), oxygen saturation, heart rate, snoring and body position.

Mrs. Rayna Dong, Dehaier's Marketing Director, commented, "We have listened to feedback from doctors, patients, distributors and manufacturers to improve our already-powerful sleep diagnostics product. We added two new important channels to improve the accuracy of sleep diagnosis. We also enhanced the user interface to make the device's features even easier to use and optimized the operating system. We expect the new device will be ready to enter market near the end of this year. We plan to attend domestic and international exhibitions to show the world the new device beginning in 2014."

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). More information may be found at http://www.dehaier.com.cn

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular any implications regarding the sleep diagnostic device. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Dehaier Medical Systems Limited
Surie Liu
+86 10-5166-0080


Dehaier Medical Systems Limited
Tina He
+86 10-5166-0080